Decision on CF drug will fall to next government
Vertex Pharmaceuticals has made a submission to the state’s cost-effectiveness watchdog for the approval of its cystic fibrosis drug Orkambi.
The National Centre for Pharmacoeconomics (NCPE) is due to make a recommendation on whether the state should fund the new drug before the end of June. Cystic Fibrosis Ireland has described Orkambi as a “gamechanger” and said it would extend the lives of sufferers, who rarely live beyond their 40s.
Vertex wants to ...